Cystatin C as Prognostic Biomarker in ST-Segment Elevation Acute Myocardial Infarction

Serum extracellular vesicle protein levels are associated with acute coronary syndrome

“…Serum levels are regarded as a strong marker of kidney function, 29 but cystatin C is also associated with CVD independently of renal disease. 30,31 Serum cystatin C has been established as a predictor of cardiovascular events and mortality in patients with non-ST-elevation ACS, 32,33 ST-elevation myocardial infarction, 34 and suspected ACS, 35 but also in the general population 36 and elderly persons. 37 Although the predictive potential in CVD seems to be high, the diagnostic value of cystatin C for acute myocardial ischaemia remains unexplored so far.…”

Association of Cystatin C with Measures of Obesity and Its Impact on Cardiovascular Events Among Healthy US Adults

“…1,5,18 In a recent report, CysC was shown to be strongly associated with all-cause and cardiovascular mortality in a cohort of patients referred for coronary angiography. 19 Its ability to reliably predict preclinical renal disease 20 as well as its plausible role in inflammation and atherogenesis 21 may explain its utility in the prognostication of CVD mortality.…”

Association of serum cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with anterior wall ST elevation myocardial infarction treated with primary coronary intervention

“…A previous study by Ichimoto et al [20] showed that in patients with STEMI treated by PPCI, a higher cystatin C level was associated with a higher incidence of rehospitalization for heart failure. Silva et al [11] showed that in patients with STEMI treated by PPCI, those with elevated cystatin C levels have an approximately 5 times greater risk of progression to cardiogenic shock or death during hospitalization, and were associated with an increased risk of death or reinfarction at long-term follow-up. In accordance with these recent publications, the present study also demonstrated that in patients with STEMI treated by PPCI, elevated admission cystatin C levels are associated with poor short-term outcomes, which is mainly manifested as a poor regional LV functional recovery, LVR together with an increased incidence of CHF at 6-month follow-up.…”

“…Apart from its established role in evaluating renal function, cystatin C has also proven to be a powerful predictor of mortality and adverse cardiovascular events in postmenopausal women with angiographically documented coronary artery disease [7], in patients with heart failure [8] and in patients with non-ST elevation acute coronary syndrome [9], and in stable CAD patients with preserved eGFR after elective PCI [10]. Furthermore, elevated systemic cystatin C levels have recently been reported to predict a poor prognosis in patients with STEMI treated by PPCI [11]. However, whether cystatin C may exert its detrimental effects in STEMI patients by favoring the no-reflow phenomenon and adverse LV remodeling has not been fully evaluated so far.…”